2024-11-19 15:34:52
Sciwind Biosciences Announces Positive Topline Results from 20-week Phase 2 Clinical Trial of XW003 (Ecnoglutide), a novel long-lasting GLP-1 analogue, in Adult Patients with Type 2 Diabetes in China
Health/ 2023-07-22
Sciwind Biosciences Announces Positive T...

- Robust HbA1c reduction of 2.4% was observed with 1.2 mg XW003 dose - Up to 88% of participants achieved HbA1c ≤ 7% and up to 72% achieved...

Lynk Pharmaceuticals Announces IND Approval of LNK01004 for Atopic Dermatitis in China
Health/ 2023-07-22
Lynk Pharmaceuticals Announces IND Appro...

HANGZHOU,China,Aug. 3,2022-- Lynk Pharmaceuticals Co.,Ltd. (hereinafter referred to as \'Lynk Pharmaceuticals\'),an innovative clinical stag...

CUSMail

CusMail provide the Latest News , Business and Technology News Release service. Most of our news is paid for distribution to meet global marketing needs. We can provide you with global market support.

© CUSMAIL. All Rights Reserved. Operate by Paid Release